Correction: Lipoprotein Lipase SNPs rs13702 and rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients

In Table 2, in the PDF version of the article, the first row is incorrectly replicated at the beginning of each new page. Please see the corrected Table 2 here.

Table 2. Clinical and biological characteristics among LPL rs301, rs328 and rs13702 Genotypes.

	rs301 TT		rs301 TC/CC
Characteristic	n	%	n	%	p a
No of patients	146	59.1	101	40.9
HWE c		58.0		42.0	0.322
Gender
Male	100	59.2	69	40.8	1.000
Female	46	59.0	32	41.0
Median age at diagnosis	63		62		0.651 b
Age
<60 years	59	60.8	38	39.2	0.786
≥60 years	85	58.2	61	41.8
Binet stage
A	106	57.9	77	42.1	0.404
B/C	31	66.0	16	34.0
IGHV
Mutated	74	58.7	52	41.3	0.972
Unmutated	48	60.0	32	40.0
CD38
<7%	68	54.8	56	45.2	0.224
≥7%	65	63.7	37	36.3
ZAP70
<20%	75	60.5	49	39.5	1.000
≥20%	54	61.4	34	38.6
LPL
negative	62	63.3	36	36.7	0.821
positive	57	60.6	37	39.4
LDT
≥ 1 year	71	61.2	45	38.8	0.662
< 1 year	55	57.3	41	42.7
Cytogenetics
normal	36	61.0	23	39.0	0.590
chromosomal aberrations	87	55.8	69	44.2
Del13q
absent	68	63.6	39	36.4	0.232
present	51	54.3	43	45.7
Del11q
absent	109	58.3	78	41.7	0.606
present	11	50.0	11	50.0
Del17p
absent	106	55.5	85	44.5	0.563
present	13	65.0	7	35.0
	rs328 CC		rs328 CG/GG
Characteristic	n	%	n	%	P a
No of patients	195	78.6	53	21.4
HWE c		77.9		22.2	0.123
Gender
Male	134	78.8	36	21.2	1.000
Female	61	78.2	17	21.8
Median age at diagnosis	62		62		0.878 b
Age
<60 years	79	80.6	19	19.4	0.752
≥60 years	114	78.1	32	21.9
Binet stage
A	144	78.3	40	21.7	0.610
B/C	39	83.0	8	17.0
IGHV
Mutated	104	81.9	23	18.1	0.421
Unmutated	61	76.3	19	23.8
CD38
<7%	99	79.8	25	20.2	0.954
≥7%	81	78.6	22	21.4
ZAP70
<20%	99	79.2	26	20.8	0.867
≥20%	68	77.3	20	22.7
LPL
negative	83	84.7	15	15.3	0.483
positive	75	79.8	19	20.2
LDT
≥ 1 year	92	79.3	24	20.7	1.000
< 1 year	77	79.4	20	20.6
Cytogenetics
Normal	46	78.0	13	22.0	1.000
Chromosomal aberrations	123	78.3	34	21.7
Del13q
absent	85	78.7	23	21.3	1.000
present	74	78.7	20	21.3
Del11q
absent	150	79.8	38	20.2	0.144
present	14	63.6	8	36.4
Del17p
absent	149	77.6	43	22.4	0.316
present	18	90.0	2	10.0
	rs13702 TT		rs13702 TC/CC
Characteristic	n	%	n	%	p a
No of patients	123	50.0	123	50.0
HWE c		49.1		50.9	0.413
Gender
Male	87	51.5	82	48.5	0.582
Female	36	46.8	41	53.2
Median age at diagnosis	63		62		0.501 b
Age
<60 years	48	49.5	49	50.5	1.000
≥60 years	73	50.3	72	49.7
Binet stage
A	87	47.8	95	52.2	0.202
B/C	28	59.6	19	40.4
IGHV
Mutated	61	48.8	64	51.2	0.369
Unmutated	45	56.3	35	43.8
CD38
<7%	58	47.5	64	52.5	0.551
≥7%	54	52.4	49	47.6
ZAP70
<20%	62	50.0	62	50.0	0.663
≥20%	47	54.0	40	46.0
LPL
negative	49	50.5	48	49.5	0.877
positive	49	52.7	44	47.3
LDT
≥ 1 year	61	53.5	53	46.5	0.298
< 1 year	44	45.4	53	54.6
Cytogenetics
Normal	29	50.0	29	50.0	1.000
Chromosomal aberrations	77	49.4	79	50.6
Del13q
absent	55	51.4	52	48.6	0.968
present	49	52.7	44	47.3
Del11q
absent	96	51.6	90	48.4	0.126
present	7	31.8	15	68.2
Del17p
absent	93	48.9	97	51.1	0.920
present	9	45.0	11	55.0

^a Cross-tabulations of prognostic markers versus LPL SNP genotypes. p values of Pearson χ² statistics (with the Yates continuity correction for 2x2 tables)

^b p value of Mann-Whitney non parametric test comparing median age at diagnosis between LPL SNP genotypes

^c HWE, Hardy-Weinberg equilibrium

Table 3 has been corrected for improved readability. Please see the corrected Table 3 here.

Table 3. Survival data for different biological and clinical characteristics and LPL SNPs.

Characteristic	Median OS b	p a	Median TFS b	p a
Binet stage
A	UD c	0.002	87.2	< 0.0001
B/C	137.2		29.0
IGHV
Mutated	UD	< 0.0001	101.0	< 0.0001
Unmutated	165.0		36.0
CD38
<7%	UD	0.042	97.0	<0.0001
≥7%	UD		40.4
ZAP70
<20%	UD	0.006	97.0	< 0.0001
≥20%	170.0		36.0
LPL
Negative	UD	0.282	89.9	0.001
Positive	UD		41.6
LDT
≥ 1 year	UD	0.167	88.1	0.001
< 1 year	UD		41.6
Cytogenetics
Normal	UD	0.124	96.0	0.016
Chromosomal aberrations	UD		61.0
Del13q
absent	UD	0.168	67.0	0.748
present	UD		73.0
Del11q
absent	UD	0.854	73.0	0.244
present	UD		36.0
Del17p
absent	UD	0.008	75.7	0.016
present	133.0		26.7
LPLrs301
TT	UD	0.026	72.0	0.953
TC/CC	UD		93.7
LPLrs328
CC	UD	0.483	75.7	0.477
CG/GG	UD		67.0
LPLrs13702
TT	UD	0.008	66.0	0.678
TC/CC	UD		87.2

^a p values of log-rank tests

^b Survival curves for overall survival (OS) and treatment free survival (TFS) were estimated by the Kaplan-Meier method

^c UD, undetermined, indicating that the median value was not reached

The publisher apologizes for the errors.